Monday, 20 April 2009

Budesonide Respules (Pulmicort) inhalation suspension: US court bars Apotex from generic launch till final decision on permanent injunction

In continuation of our earlier post on Budesonide Here, Here, wherein, Innovator Astra filed a lawsuit in the US District Court for the District of New Jersey against Apotex (Apotex) filed a motion for Interim Relief seeking to prohibit sales of Apotex’s generic product until the patent infringement case has concluded.

The District Court for the District of New Jersey gave the drugmaker a restraining order (as reported by Astra in press release Here) that bars Apotex from selling a copycat version of AstraZeneca's top-selling asthma medicine Budesonide Respules (Pulmicort) inhalation suspension. Also, Court will decide by month end on permanent injunction.

Earlier, innovator was sucessful against generic launch by Teva. Later on, Teva settled with innovator and agreed to launch generic version in Dec, 2009 under licensing agreement.

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker